Intel upgraded, Reddit initiated: Wall Street's top analyst calls

1 hour ago 1

The Fly

Tue, April 21, 2026 astatine 9:03 AM CDT 3 min read

The astir talked astir and marketplace moving probe calls astir Wall Street are present successful 1 place. Here are today's probe calls that investors request to know, arsenic compiled by The Fly.

Top 5 Upgrades:

HSBC upgraded Intel (INTC) to Buy from Hold with a terms people of $95, up from $50. While foundry deals person driven a 60% rally successful the shares, Intel's "significant" server processor momentum is not priced into the stock, the steadfast tells investors successful a probe note. BNP Paribas besides upgraded Intel, but to Neutral from Underperform with a $60 terms target.
KeyBanc upgraded CrowdStrike (CRWD) to Overweight from Sector Weight with a $525 terms target. The steadfast sees Mythos arsenic a catalyst for accelerating AI-driven cybersecurity demand.
Rothschild & Co Redburn upgraded Colgate-Palmolive (CL) to Buy from Neutral with a terms people of $100, up from $93. The steadfast says its investigation of the location and idiosyncratic attraction abstraction pursuing the caller selloff yields a favorable outlook for Colgate.
Morgan Stanley upgraded Arrowhead (ARWR) to Overweight from Equal Weight with a terms people of $100, up from $78. The steadfast sees the stock's momentum continuing up of Phase 3 terrible hypertriglyceridemia information successful Q3.
Raymond James upgraded Ball Corp. (BALL) to Outperform from Market Perform with a $73 terms target. The steadfast views the institution arsenic the astir "buttoned up" connected outgo pass-throughs and hedges.

Top 5 Downgrades:

Wolfe Research downgraded Exxon Mobil (XOM) to Peer Perform from Outperform without a terms target. The steadfast cites valuation for the downgrade pursuing the stock's beardown stock performance.
Baird downgraded Mohawk Industries (MHK) to Neutral from Outperform with a terms people of $118, down from $156. The firm's Q1 transmission checks bespeak residential gathering merchandise enactment remains lackluster, with spending weakness continuing and task indicators mixed.
Wedbush downgraded Passage Bio (PASG) to Neutral from Outperform with a terms people of $8, down from $32. The steadfast cites Monday's regulatory update that a randomized controlled registrational survey volition beryllium required to enactment PBFT02's FDA support for the attraction of FTD-GRN. TD Cowen besides chopped Passage Bio to Hold from Buy with nary terms target.
UBS downgraded Xylem (XYL) to Neutral from Buy with a terms people of $132, down from $152. The steadfast sees adjacent word task hold risks impacting the company's integrated growth.
Wolfe Research downgraded Valero (VLO) to Underperform from Peer Perform with a $203 terms target. Wolfe sees hazard that the "elevated" escaped currency travel expectations implied by Valero's existent valuation cannot beryllium supported.